Edition:
India

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

14.85USD
20 Apr 2018
Change (% chg)

$0.10 (+0.68%)
Prev Close
$14.75
Open
$14.70
Day's High
$14.95
Day's Low
$14.68
Volume
110,447
Avg. Vol
165,174
52-wk High
$20.35
52-wk Low
$11.90

Latest Key Developments (Source: Significant Developments)

Vanda Pharmaceuticals Wins Appeal Case On Fanapt
Friday, 13 Apr 2018 

April 13 (Reuters) - Vanda Pharmaceuticals Inc ::VANDA WINS APPEAL CASE ON FANAPT®.U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT.'610 PATENT IS SET TO EXPIRE NOVEMBER 2, 2027.  Full Article

Vanda receives negative opinion for marketing authorization from the European Medicines Agency
Saturday, 11 Nov 2017 

Nov 10 (Reuters) - Vanda Pharmaceuticals Inc ::Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia.Vanda Pharmaceuticals Inc - ‍CHMP re-examined its negative opinion and confirmed refusal of fanaptum MAA​.  Full Article

Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Vanda Pharmaceuticals Inc :Qtrly ‍net loss per share $0.10​.  Full Article

Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Vanda Pharmaceuticals Inc :Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds.Vanda Pharmaceuticals - Pricing agreement for treatment of totally blind individuals with sleep-wake disorder with Hetlioz after an arbitration board decision.Vanda Pharmaceuticals - ‍Ex-factory price of Hetlioz in Germany expected to be about eur 69,000/year, effective date of Aug 1, 2017​ - SEC Filing.  Full Article

Vanda says U.S. District Court ruled Roxane Laboratories infringed certain patents
Friday, 26 Aug 2016 

Vanda Pharmaceuticals Inc :U.S. District Court ruled that Roxane Laboratories infringed U.S. patent nos. RE39,198 and 8,586,610 by submitting to FDA an ANDA.  Full Article

Vanda Pharmaceuticals Q2 loss per share $0.11
Thursday, 28 Jul 2016 

Vanda Pharmaceuticals Inc : Vanda pharmaceuticals reports second quarter 2016 financial results . Vanda reiterates 2016 net product sales guidance of $143 million to $153 million . Qtrly loss per share $0.11; revenue $36.03 million . Says reiterates its prior 2016 financial guidance . Hetlioz net product sales grew to $17.5 million , fanapt net product sales grew to $18.6 million in q2 2016 .Says year end 2016 cash is expected to be between $123 and $143 million.  Full Article

Vanda says FDA approved NDA for drug to treat schizophrenia in adults
Friday, 27 May 2016 

Vanda Pharmaceuticals Inc : New approved PI now includes placebo-controlled, long-term study data .Vanda announces FDA approval of the Fanapt supplemental new drug application for maintenance treatment of schizophrenia in adults.  Full Article

BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt

* U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT